Early detection of hepatocellular carcinoma by Hyperpolarized [1-13C]pyruvate MRI

Aarhus University, The MR Research Center0 个研究点目标入组 46 人开始时间: 2021年3月4日最近更新: 2024年8月5日

适应症

试验速览

暂无简介。

•All participants:
•-Aged 18 – 85 years. The age and gender of the healthy controls of the main study will be matched to the participating patients.
•-Pre-menopausal women must be confirmed non-pregnant by an onsite test
•HCC group:
•-Diagnosed HCC larger than 10 mm confirmed by standard MRI, or CT or confirmed by tumour biopsy.
•-Subgroup 1: Not elected for liver surgery
•-Subgroup 2: Elected for liver surgery
•Small tumor group:
•-One or more small lesions in the liver requiring 2 years of repeated follow-up as per the EASL guideline. Could be in a liver with a confirmed HCC.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 16

•Contraindications for MRI with contrast:
•-Chronic kidney disease
•-Patients with tumors must have eGFR > 30 ml/min/1.73m2
•-Significant cardiac disease (as left ventricular outflow obstruction or heart failure)
•-Significant obstructive lung disease or severe asthma
•-Pacemaker, neurostimulator or cholera implant
•-Metal foreign bodies such as fragments and irremovable piercings
•-Unsafe medical implants (safety of heart valves, hips and the like must be confirmed)
•-Claustrophobia
•-Largest circumference including arms > 160 cm
•Competing systemic disease including diabetes (hypertension, dyslipidemia, diabetes etc. allowed)
•Hepatic encephalopathy = grade 2.
•Stents or other devices implanted close to the liver that may cause imaging artefacts
•Allergy to pyruvate

发起方

Aarhus University, The MR Research Center